In Maryland, scientific discovery rarely slows progress. Laboratories across the state generate breakthrough therapeutics, diagnostics, and medical technologies at remarkable speed. Moving those innovations beyond the lab and into the hands of patients and investors requires a different kind of expertise, grounded in market insight, capital strategy, and disciplined execution. BioHealth Innovation was created to guide that transition.
Working at the intersection of science, capital, and strategy, BioHealth Innovation partners with entrepreneurs, research institutions, federal laboratories, and investors to help promising technologies take shape as sustainable companies.
“We exist to move science out of the lab and into the marketplace where it can change lives,” says President and CEO Rich Bendis. “Maryland has extraordinary assets. Our role is to help innovators navigate the path from discovery to commercialization.”
Maryland’s position within the BioHealth Capital Region unites world-class universities, leading research institutions, and federal agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). The concentration of expertise drives continuous discovery, and building durable companies from that discovery requires careful navigation of regulatory pathways, reimbursement strategy, early financing, and operational growth. Without coordinated guidance, promising advances can lose momentum long before they reach patients.
Structuring the Path Forward
Early-stage life sciences ventures face a demanding stretch: founders evaluate market need, map out development steps, and engage investors, often while the science is still evolving.
BioHealth Innovation brings that clarity into focus. The team provides commercialization planning, market analysis, capital formation support, and strategic guidance tailored specifically to life sciences companies. Some clients are preparing for their first institutional financing while others are refining positioning or entering new markets. In each case, the emphasis remains on practical execution. “We aren’t a passive resource,” he explains. “We assess the science, evaluate the market, identify the right partners, and prepare companies for investors. The work is disciplined and focused on results.”
The organization also helps move federally developed technologies into private sector opportunity. Maryland’s federal laboratories produce significant intellectual property, yet building companies around those discoveries demands deliberate evaluation and thoughtful planning. This firm assesses commercial potential, structures licensing pathways, supports startup formation, and assists in assembling leadership teams capable of guiding companies through growth. “Great science alone isn’t enough,” he says. “Investors need to see a clear path to market, experienced leadership, and a compelling value proposition.”
Capital, Confidence, and Leadership
Emerging life sciences companies often encounter complex hurdles when raising capital. The organization cultivates relationships with venture firms, angel investors, and strategic partners while helping founders present their opportunities with precision. Investor forums and regional summits expand Maryland’s visibility within national networks and strengthen dealflow across the ecosystem. “Capital follows confidence,” he notes. “When investors understand the depth of innovation here and see companies that are prepared and disciplined, they engage.”
Preparation goes beyond refining a pitch deck: companies receive guidance on valuation strategy, competitive positioning, differentiation, and long-term growth planning. That groundwork makes fundraising smoother and helps young companies withstand early setbacks.
Leadership often determines whether science scales. Many founders bring deep technical expertise but are stepping into executive roles for the first time. The organization mentors emerging leaders through governance decisions, regulatory considerations, and expansion planning while encouraging the formation of experienced boards and advisory networks.
“Entrepreneurs are often experts in their science,” he says. “They may be first-time CEOs. We provide the network and strategic guidance that help them grow into those roles.”
Impact Beyond the Laboratory
The effects extend well beyond individual ventures. Each funded startup, licensing agreement, and new job contributes to Maryland’s economic strength. The life sciences sector attracts external investment and supports high-value employment across research, manufacturing, and professional services.
The organization approaches its work with that broader picture in mind: success for one company strengthens confidence across the region and reinforces the ecosystem as a whole. “We think about impact at multiple levels,” he explains. “Patient impact, company impact, and regional impact. When a company secures funding or closes a partnership, that success strengthens the ecosystem.”
Innovation across biotechnology, precision medicine, and digital health rarely stands still. As discoveries move from concept toward application, BioHealth Innovation collaborates with federal and academic partners to help companies keep momentum.
“Our region has everything it needs to lead,” he says. “World-class science, entrepreneurial talent, and a collaborative culture. The future depends on how effectively we connect those elements.”
Discovery starts in Maryland’s labs. BioHealth Innovation makes sure it does not end there.
